In another study, 17% of ~17,500 gastrointestinal tumours had alterations in one or more of the 10 DDR genes that are known therapeutic targets18 and 21% of tumours with DDR GAs had high TMB, supporting the potential use of a combination of DDR inhibition with immunotherapy18. The gene discussed is DDR1; the disease is neoplasm.